Abzena – US Headquarters
6325 Lusk Blvd., San Diego, CA 92121
T: (858) 550-4094
Abzena – UK Headquarters
Babraham Research Campus
Cambridge, UK CB22 3AT
T +44 1223 903498
E: info@abzena.com
LinkedIn: https://www.linkedin.com/company/abzena/
W: Abzena.com
Abzena is the leading end-to-end CDMO + CRO for bioconjugates, ADCs and complex biologics. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule.
Over the past 20 years, Abzena has helped hundreds of customers ranging from emerging biotechs to the top large pharmaceutical firms achieve their regulatory and clinical milestones. With extensive scientific knowledge and technical expertise, our global teams provide customers with comprehensive support that minimizes risks and moves new medicines forward faster- with greater success. Our global locations include San Diego (CA, USA), Bristol (PA, USA), and Cambridge (UK).
Comprehensive biologics & bioconjugate support:
Monoclonal Antibodies (mAbs), Antibody Fragments (fAbs), Antibody-Drug Conjugates (ADCs), Antibody-Oligonucleotide Conjugates (AOCs) Bispecific Antibodies (bsAbs), Radioconjugates (RDCs/RACs) Fusion Proteins, Cytokines, Recombinant & Conjugate Vaccines, and Biosimilars
Services that expedite timelines
Abzena develops and implements fully integrated services and tailored, innovative solutions that are designed to rapidly advance your program to its next milestone.
Solutions for improving development
Our proprietary solutions are designed to give your program the best chance of clinical and commercial success.
AbZelectPRO™ – high-yielding mammalian cell line development (CLD) platform for accelerating the generation of production cell lines in just 10 weeks with 8g/L in high-performing titres for antibodies, bispecifics and recombinant proteins.
EpiScreen™ 2.0- a comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy. This high sensitivity, multi-dimensional, data-rich platform streamlines candidate selection, helping to de-risk the drug development process
Composite Human Antibody™ – a platform used for designing safer, more effective, humanized antibodies.
Composite Proteins™ – a deimmunization technology that designs safer therapeutic proteins, devoid of human T cell epitopes, to minimize potential immunogenicity in patients without compromising activity.
ThioBridge™- a next generation conjugation linker technology proven to enhance ADC development by overcoming issues with existing technologies to improve stability, potency, and efficacy.
LabZient™– our analytical platform that combines predictive in-silico evaluation with laboratory methods to de-risk the application of platform analytical procedures and expedites the pathway to IND.
The Abzena Approach
We are focused on getting it right from the start. From early discovery through commercial, our experienced scientists work with you side-by-side, functioning seamlessly as part of your team—using real-world insights to bring new ideas to the table and then turning them into action. With quality top of mind, we plan the best route, steering your drug program toward regulatory approval, and getting it into the hands of patients.
Connect with us today at info@abzena.com or by visiting Abzena.com to discuss your drug program’s needs with our experts.
Posted Date: 12/1/2024
This record has been viewed 381 times.